Ulcerative pyoderma gangrenosum is a rare, inflammatory skin condition characterized by rapidly progressing, painful ulcers that can significantly impact quality of life. Rejuvenation Dermatology’s Clinical Trials Division is actively supporting research focused on advancing treatment options for this complex condition. Through participation in these studies, patients may gain access to innovative therapies designed to reduce inflammation, promote wound healing, and improve overall disease control. Conducted across our network of dermatology-led research sites in Edmonton, Vancouver, Calgary, and Oakville, each trial follows strict regulatory standards and Good Clinical Practice guidelines to ensure patient safety and high-quality data. Participants are supported by experienced dermatology teams throughout every stage of the clinical trial process.
EVIDENCE DRIVES ADVANCED TREATMENT FOR INFLAMMATORY SKIN ULCERS
We believe effective treatment for ulcerative pyoderma gangrenosum must go beyond symptom control. Our clinical trials are designed to evaluate emerging therapies that target the underlying immune dysfunction driving inflammation and tissue damage, generating data that supports meaningful advancements in care and long-term disease management.
RESEARCH INTEGRATED INTO REAL CLINICAL PRACTICE
Clinical trials are conducted within our dermatology clinics, allowing patients to receive care in a trusted, physician-led environment. Our dermatologists understand the complexity and severity of ulcerative pyoderma gangrenosum and provide personalized, medically guided support throughout each stage of the study, with a focus on wound healing, pain management, and overall patient wellbeing.
ETHICS ARE NON-NEGOTIABLE
All ulcerative pyoderma gangrenosum trials undergo independent ethics board review prior to patient enrollment. Participants are fully informed, carefully screened, and closely monitored throughout the study, with safety protocols that meet and exceed regulatory and Good Clinical Practice standards.
STANDARDIZED, NATIONAL EXECUTION
Our clinical research network operates under centralized oversight with standardized protocols across all locations. This ensures consistency in patient care, efficient study execution, and the generation of high-quality, reliable data across our sites in Edmonton, Vancouver, Calgary, and Oakville.
Clinical research at Rejuvenation Dermatology is driven by a commitment to advance patient care through evidence-based medicine. Through participating in regulated clinical trials, the organization helps to shape development of safer, more effective dermatologic treatments while ensuring patients receive care that meets the highest ethical and scientific standards.
Participation in clinical research enables Rejuvenation physicians to remain at the forefront of dermatologic innovation and provides patients with access to therapies that may not yet be commercially available.
DERMATOLOGY-LED RESEARCH
All clinical trials are conducted under the supervision of board-certified dermatologists with experience in diagnosing and managing hair loss disorders. Patients receive expert care throughout every stage of participation.
NATIONAL REACH, LOCAL CARE
With multiple research sites across Canada, we combine the scale required for high-quality clinical research with the personalized care of local dermatology clinics, delivering consistency without sacrificing patient experience.
SAFETY FIRST, ALWAYS
Patient safety is our top priority. Strict eligibility criteria, continuous monitoring, and adherence to Good Clinical Practice (GCP) standards ensure a safe and controlled research environment.
RELIABLE DATA, TRUSTED BY SPONSORS
Our structured processes and experienced teams allow us to deliver consistent, high-quality data. This level of rigor ensures a seamless experience for both sponsors and participants.
RESEARCH WITH REAL IMPACT
Participation in ulcerative pyoderma gangrenosum clinical trials contributes to the advancement of therapies targeting complex immune-mediated skin conditions. Patients play an active role in helping shape future treatment approaches aimed at improving healing, reducing recurrence, and elevating standards of care.
Participants typically go through several stages, including pre-screening, an in-clinic screening visit, and enrollment if eligible. Once enrolled, patients attend scheduled follow-up visits for monitoring, treatment administration, and assessments. Throughout the study, participants are supported by experienced dermatology teams and closely monitored to ensure safety and care quality.
Eligibility is determined based on specific study criteria, which may include factors such as age, medical history, current health status, and confirmed diagnosis of ulcerative pyoderma gangrenosum. Participation is open to both existing patients and the public, with no referral required. A pre-screening process is conducted to assess suitability.
Ulcerative pyoderma gangrenosum is a rare, inflammatory skin condition that causes painful, rapidly progressing ulcers. It is considered an immune-mediated disorder, often associated with underlying systemic conditions, and requires specialized dermatologic care for proper diagnosis and management.
ULCURATIVE PYODERMA GANGRENOSUM CLINICAL TRIALS | CLINICAL TRIALS CANADA | REJUVENATION DERMATOLOGY
Rejuvenation Dermatology’s Clinical Trials Department is a national, multi-site research network dedicated to advancing dermatologic care through ethically conducted, regulated clinical research. Integrated within routine clinical practice, the department partners with global pharmaceutical sponsors to evaluate novel therapies and offers early access to innovative treatment options. The team supports industry-sponsored and investigator-initiated trials across a broad range of indications, collaborating closely with sponsors, CROs, investigators, and ethics boards to deliver high-quality data while maintaining a strong commitment to patient safety.
Since its inception, the division has evolved from a single research-focused clinic into a coordinated, multi-province research network. Today, it operates with standardized infrastructure, centralized oversight, and experienced investigators across Canada.
